Author Index to Volume 5

INDEX Reviews in Urology Author Index to Volume 5 Amato, Robert J. Vaccine therapy for renal cell carcinoma. 5(2):65-71. Anagnostou, Theodore Artificial neural networks for decisionmaking in urologic oncology. 5(1):15-21. Appell, Rodney A. Overactive bladder in special populations. 5(suppl 8):S37-S41. Arlen, Philip M. See Leonard, Gregory D. Assimos, Dean G. Best of the 2003 AUA Annual Meeting [Meeting Review]. 5(3):156-181. Hormone replacement therapy and postmenopausal stone-formers [Literature Review]. 5(2):130. Normal-calcium, low-sodium, and lowanimal protein diet for stone prevention [Literature Review]. 5(1):60-61. See Matlaga, Brian R. See Shah, Ojas D. Updates in endourology and shock wave lithotripsy [Meeting Review]. 5(3):182185. Barada, James H. Optimizing outcomes of oral therapy for patients with erectile dysfunction. 5(suppl 7):S28-S34. Beer, Tomasz M. See Henner, William David Belldegrun, Arie S. Best of the 2003 AUA Annual Meeting [Meeting Review]. 5(3):156-181. See Kim, Hyung L. See Palapattu, Ganesh S. See Pantuck, Allan J. Brawer, Michael K. Androgen supplementation and prostate cancer risk: strategies for pretherapy assessment and monitoring. 5(suppl 1):S29-S33. 252 VOL. 5 NO. 4 2003 REVIEWS IN UROLOGY Assays for complexed prostate-specific antigen and other advances in the diagnosis of prostate cancer. 5(suppl 6):S10-S16. The role of the urologist in treating patients with hormone-refractory prostate cancer. 5(suppl 2):S48-S52. Best of the 2003 AUA Annual Meeting [Meeting Review]. 5(3):156-181. Dahut, William L. Early diagnosis and staging of prostate cancer. 5(suppl 6):S17-S22. D’Amico, Anthony V. Broderick, Gregory A. Oral pharmacotherapy and the contemporary evaluation and management of erectile dysfunction. 5(suppl 7):S9-S20. Bruskewitz, Reginald C. Quality of life and sexual function in patients with benign prostatic hyperplasia. 5(2):72-80. Cannon, Tracy W. Advances in the treatment of pelvic floor dysfunction [Meeting Review]. 5(4):235-240. Pharmacotherapy for stress urinary incontinence. 5(3):135-141. Carducci, Michael A. Prostate cancer update: advanced disease. 5(suppl 6):S47-S53. See Dreicer, Robert Chan, Daniel W. See Gretzer, Matthew B. Chancellor, Michael B. Best of the 2003 AUA Annual Meeting [Meeting Review]. 5(3):156-181. See Cannon, Tracy W. See Chermansky, Christopher J. See Kim, John See Kwon, Dong Duek See Yoshimura, Naoki Chermansky, Christopher J. Increasing awareness and improving the care of urinary incontinence [Meeting Review]. 5(1):22-25. Crawford, E. David Complementary medicine, chemoprevention, and staging of prostate cancer. 5(suppl 6):S23-S32. See Leonard, Gregory D. Therapeutic strategies for locally and locally advanced prostate cancer: combining androgen suppression with definitive local therapy. 5(suppl 6):S40-S46. deKernion, Jean B. See Freedland, Stephen J. Djavan, Bob Best of the 2003 AUA Annual Meeting [Meeting Review]. 5(3):156-181. See Anagnostou, Theodore See Seitz, Christian Dmochowski, Roger R. Treatment of the overactive bladder: where we stand in 2003. 5(suppl 8):S11S17. Dobrovits, Michael Best of the 2003 AUA Annual Meeting [Meeting Review]. 5(3):156-181. Dreicer, Robert E-1899: an eastern cooperative oncology group study comparing ketoconazole plus hydrocortisone with docetaxel plus estramustine for asymptomatic, androgen-independent, nonmetastatic prostate cancer patients with rising PSA levels. 5(suppl 2):S35-S41; 5(suppl 3):S52-S58. See Klein, Eric A. Eisenberger, Mario A. A multi-institutional pilot study of adjuvant docetaxel for patients with prostate cancer at high risk for relapse after radical prostatectomy. 5(suppl 2):S42-S47; 5(suppl 3):S59-S64. Figg, William D. See Leonard, Gregory D. Freedland, Stephen J. Role of lymphadenectomy for patients Author Index undergoing radical nephrectomy for renal cell carcinoma. 5(3):191-195. Goldfarb, David A. See Shapiro, Ellen Gonzalez-Cadavid, Nestor See Jalkut, Mark Gretzer, Matthew B. 54-year-old male with high-grade prostatic intraepithelial neoplasia on prostate biopsy. 5(1):45-48. Advances in prostate cancer treatment [Meeting Review]. 5(2):111-117. Best of the 2003 AUA Annual Meeting [Meeting Review]. 5(3):156-181. Modern tumor marker discovery in urology: surface enhanced laser desorption and ionization (SELDI). 5(2):81-89. Gulley, James L. See Leonard, Gregory D. Han, Ken-ryu See Kim, Hyung L. Harpster, Lewis E. See Lenz, Dean L. Heaton, Jeremy P.W. Hormone treatments and preventive strategies in the aging male: whom and when to treat? 5(suppl 1):S16-S21. Henner, William David A new formulation of calcitriol (DN-101) for high-dose pulse administration in prostate cancer therapy. 5(suppl 3):S38S44. Howden, Nancy See Cannon, Tracy W. Hussain, Maha H.A. See Kent, Elizabeth C. Jalkut, Mark Peyronie’s disease: a review. 5(3):142-148. Kent, Elizabeth C. Neoadjuvant therapy for prostate cancer: an oncologist’s perspective. 5(suppl 3):S28S37. Khan, Masood A. Bisphosphonates in metastatic prostate cancer [Literature Review]. 5(3):204-206. Chemoprevention and prostate cancer [Literature Review]. 5(1):61-63. Expectant management of prostate cancer [Literature Review]. 5(4):247-250. Kim, Hyung L. Late relapse of germ-cell tumor [Literature Review]. 5(3):207-208. See Palapattu, Ganesh S. Kim, John New approaches to the treatment of overactive bladder: the purine pathways and an update on the tension-free vaginal tape sling [Literature Review]. 5(1):59-60. Klein, Eric A. Initial experience with single-agent docetaxel as neoadjuvant therapy in men with locally advanced prostate cancer. 5(suppl 2):S22-S27; 5(suppl 3):S22-S27. Kumar, Parvesh A new paradigm for the treatment of highrisk prostate cancer: radiosensitization with docetaxel. 5(suppl 3):S71-S77. Kuritzky, Louis A primary care physician’s perspective on benign prostatic hyperplasia. 5(suppl 5):S42-S48. Kwon, Dong Duek The estrogen controversy Review]. 5(2):131-132. [Literature Lee, Benjamin R. Laparoscopic total and partial nephrectomy—the new standard? 5(1):9-14. Lenz, Dean L. Urothelial carcinoma in a man with hereditary nonpolyposis colon cancer. 5(1):49-53. Leonard, Gregory D. Docetaxel and thalidomide as a treatment option for androgen-independent, nonmetastatic prostate cancer. 5(suppl 3):S65S70. Lepor, Herbert Landmark studies impacting the medical management of benign prostatic hyperplasia. 5(suppl 4):S34-S41; 5(suppl 5):S28-S35. Surgical, pharmacological, and technological advances in adult and pediatric urology— state of the art [Meeting Review]. 5(1):29-39. MacDiarmid, Scott Antimuscarinic therapy for the treatment of mixed incontinence. 5(suppl 8):S18-S25. Matlaga, Brian R. Drug-induced urinary calculi. 5(4):227-231. See Shah, Ojas D. Matsumoto, Alvin M. Fundamental aspects of hypogonadism in the aging male. 5(suppl 1):S3-S10. McCullough, Andrew R. Case scenarios in androgen deficiency. 5(suppl 1):S41-S48. The penis as a barometer of endothelial health. 5(suppl 7):S3-S8. McVary, Kevin T. Clinical evaluation of benign prostatic hyperplasia. 5(suppl 4):S3-S11; 5(suppl 5):S3-S11. Meacham, Randall B. Androgen replacement therapy: treatment advances and clinical implications [Literature Review]. 5(4):245-247. Best of the 2003 AUA Annual Meeting [Meeting Review]. 5(3):156-181. See Myers, Jeremy B. See Niederberger, Craig S. Myers, Jeremy B. Androgen replacement therapy in the aging male. 5(4):216-226. Nickel, J. Curtis Benign prostatic hyperplasia: case scenarios. 5(suppl 4):S48-S49. Benign prostatic hyperplasia: does prostate size matter? 5(suppl 4):S12-S17. Best of the 2003 AUA Annual Meeting [Meeting Review]. 5(3):156-181. Chronic epididymitis: a practical approach to understanding and managing a difficult urologic enigma. 5(4):209-215. Management of urinary tract infections in children: simplifying the controversies? [Literature Review]. 5(2):132-134. Niederberger, Craig S. Male infertility. 5(3):200. Nitti, Victor W. Transdermal therapy for overactive bladder: present and future. 5(suppl 8):S31S36. O’Leary, Michael P. A new quality-of-life scoring instrument for patients with erectile dysfunction [Literature Review]. 5(4):247. Development of an index to evaluate symptoms in men with androgen deficiency. 5(suppl 1):S11-S15. Weighing cost versus efficacy in assisted reproductive technology [Literature Review]. 5(4):251. Palapattu, Ganesh S. Advances in the treatment of genitourinary cancer [Meeting Review]. 5(4):232-234. Lymph node dissection in patients with kidney cancer: when is it indicated? 5(3):196-199. Pantuck, Allan J. Best of the 2003 AUA Annual Meeting [Meeting Review]. 5(3):156-181. Urologic oncology: extraordinary opportunities for discovery [Meeting Review]. 5(1):26-28. Partin, Alan W. Best of the 2003 AUA Annual Meeting [Meeting Review]. 5(3):156-181. See Gretzer, Matthew B. See Khan, Masood A. Petrylak, Daniel P. Docetaxel for the treatment of hormonerefractory prostate cancer. 5(suppl 2):S14S21; 5(suppl 3):S14-S21. Hormone-refractory prostate cancer: new horizons. 5(suppl 6):S54-S58. Pienta, Kenneth J. See Sandler, Howard M. Rajfer, Jacob Androgen replacement and quality of life [Literature Review]. 5(3):206-207. Best of the 2003 AUA Annual Meeting [Meeting Review]. 5(3):156-181. VOL. 5 NO. 4 2003 REVIEWS IN UROLOGY 253 Author Index continued Recent findings in impotence research [Meeting Review]. 5(2):118-120. See Jalkut, Mark Remzi, Mesut Best of the 2003 AUA Annual Meeting [Meeting Review]. 5(3):156-181. See Anagnostou, Theodore See Seitz, Christian Ritchey, Michael L. See Shapiro, Ellen Roehrborn, Claus G. 5--reductase inhibitors prevent the progression of benign prostatic hyperplasia. 5(suppl 4):S18-S27; 5(suppl 5):S12-S21. Best of the 2003 AUA Annual Meeting [Meeting Review]. 5(3):156-181. See Seitz, Christian Sadovsky, Richard Asking the questions and offering solutions: the ongoing dialogue between the primary care physician and the patient with erectile dysfunction. 5(suppl 7):S35S48. Sandler, Howard M. Rationale for the radiation therapy oncology group study RTOG P-0014. 5(suppl 2): S28-S34; 5(suppl 3):S45-S51. Seitz, Christian Advances in the medical treatment of prostate cancer, bladder cancer, renal cell cancer, and benign prostatic hyperplasia [Meeting Review]. 5(2):90-110. Shah, Ojas D. 20-year-old male with recurrent right flank pain. 5(2):126-129. See Matlaga, Brian R. Selecting treatment for distal ureteral calculi: shock wave lithotripsy versus ureteroscopy. 5(1):40-44. Shapiro, Ellen 3-month-old boy with a febrile urinary 254 VOL. 5 NO. 4 2003 REVIEWS IN UROLOGY tract infection. 5(4):241-244. Best of the 2003 AUA Annual Meeting [Meeting Review]. 5(3):156-181. Management of vesicoureteral reflux. 5(2):121-125. The congenital and acquired solitary kidney. 5(1):2-8. Updates in pediatric urology [Meeting Review]. 5(3):186-190. Shariat, Shahrokh F. Peripheral blood RT-PCR assays for detection and prognosis of prostate cancer [Literature Review]. 5(1):54-58. Slawin, Kevin M. See Shariat, Shahrokh F. The medical therapy of prostatic symptoms study: what will we learn? 5(suppl 4): S42-S47; 5(suppl 5):S36-S41. Snow, Brent See Shapiro, Ellen Soule, Howard R. CaP CURE initiatives and projects. 5(suppl 2):S60-S65; 5(suppl 3):S92-S97. Staskin, David R. Transdermal systems for overactive bladder: principles and practice. 5(suppl 8): S26-S30. Steidle, Christopher P. New advances in the treatment of hypogonadism in the aging male. 5(suppl 1):S34S40. Stein, Richard A. Endothelial dysfunction, erectile dysfunction, and coronary heart disease: the pathophysiologic and clinical linkage. 5(suppl 7):S21-S27. Syed, Samira Innovative therapies for prostate cancer treatment. 5(suppl 3):S78-S84. Taneja, Samir S. A multidisciplinary approach to the manage- ment of hormone-refractory prostate cancer. 5(suppl 2):S53-S59; 5(suppl 3):S85-S91. Optimizing prostate biopsy strategies for the diagnosis of prostate cancer. 5(3):149-155. Taplin, Mary-Ellen Biochemical (prostate-specific antigen) relapse: an oncologist’s perspective. 5(suppl 2):S3-S13; 5(suppl 3):S3-S13. Tenover, J. Lisa The androgen-deficient aging male: current treatment options. 5(suppl 1):S22-S28. Tewari, Ashutosh Management of clinically localized prostate cancer: pathologic processing to robotic prostatectomy. 5(suppl 6):S33-S39. Tolcher, Anthony See Syed, Samira Torimoto, Kazumasa Best of the 2003 AUA Annual Meeting [Meeting Review]. 5(3):156-181. Vaughan, E. Darracott Long-term experience with 5--reductase inhibitors. 5(suppl 4):S28-S33; 5(suppl 5):S22-S27. Veltri, Robert W. See Gretzer, Matthew B. Wilt, Timothy J. Prostate cancer: epidemiology and screening. 5(suppl 6):S3-S9. Xavier, Macrina See Cannon, Tracy W. Yoshimura, Naoki Neurophysiology of lower urinary tract function and dysfunction. 5(suppl 8):S3S10. Zaontz, Mark See Shapiro, Ellen Zisman, Amnon See Pantuck, Allan J.